SOLV Solventum Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1964738 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-89.8%
TTM EPS YoY-89.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin54.8%
Operating margin5.6%
Net margin1.9%
FCF margin0.0%
EBITDA margin9.6%
Returns
ROE3.2%
ROA1.1%
ROIC (approx.)4.7%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets66.1%
Debt / equity1.05x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.99x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $8.32B | $8.25B | $8.20B | $8.13B |
| Gross profit | $4.45B | $4.59B | $4.69B | $4.70B |
| R&D expense | $739.00M | $775.00M | $758.00M | $767.00M |
| SG&A expense | $3.08B | $2.78B | $2.30B | $2.23B |
| Operating income | $2.18B | $1.04B | $1.69B | $1.69B |
| Pretax income | $1.71B | $605.00M | $1.67B | $1.69B |
| Income tax | $157.00M | $127.00M | $321.00M | $349.00M |
| Net income | $1.56B | $479.00M | $1.35B | $1.34B |
| EBITDA | $2.67B | $1.59B | $2.25B | $2.27B |
| EPS (basic) | 8.94 | 2.77 | 7.79 | 7.78 |
| EPS (diluted) | 8.88 | 2.76 | 7.79 | 7.78 |
| Weighted avg. shares (diluted) | 175.30M | 173.70M | 172.70M | 172.70M |
| Balance sheet | ||||
| Cash & equivalents | $878.00M | $762.00M | $194.00M | $61.00M |
| Receivables | $1.03B | $1.04B | $1.31B | — |
| Inventory | $1.07B | $965.00M | $857.00M | — |
| Current assets | $3.86B | $3.25B | $2.52B | — |
| PP&E, net | $1.33B | $1.62B | $1.46B | — |
| Goodwill | $5.70B | $6.38B | $6.54B | $6.43B |
| Intangibles | $2.59B | $2.54B | $2.90B | — |
| Total assets | $14.29B | $14.46B | $13.94B | — |
| Current liabilities | $3.14B | $2.70B | $1.73B | — |
| Short-term debt | $0 | $200.00M | $0 | — |
| Long-term debt | $5.04B | $7.81B | $0 | — |
| Total debt | $5.04B | $8.01B | $0 | — |
| Total liabilities | $9.24B | $11.50B | $2.28B | — |
| Shareholders' equity | $5.05B | $2.96B | $11.67B | $11.74B |
| Net debt | $4.16B | $7.25B | -$194.00M | — |
| Shares outstanding | 173.49M | 172.79M | 0 | — |
| Cash flow statement | ||||
| Operating cash flow | $369.00M | $1.19B | $1.92B | $1.68B |
| Capital expenditure | $379.00M | $380.00M | $290.00M | $251.00M |
| Free cash flow | -$10.00M | $805.00M | $1.62B | $1.43B |
| Investing cash flow | $2.80B | -$380.00M | -$230.00M | -$253.00M |
| Financing cash flow | -$3.06B | -$240.00M | -$1.55B | -$1.46B |
| Depreciation & amortization | $489.00M | $555.00M | $561.00M | $578.00M |
| Stock-based compensation | $161.00M | $112.00M | $39.00M | $37.00M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.